RxDoctor Payments Data

Adam Reynolds, MD

Neurology · Boston, MANPI 1902196090

Payments from drug & device makers

$10,417in general payments, 2019–2025

Across 174 payments — averaging $59.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Lundbeck LLC$2K
  • Argenx US, Inc.$1K
  • Boston Scientific$1K
  • Nevro Corp.$1K
  • AbbVie$449
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$1,12511%
  • Speaking & faculty fees$1,66416%
  • Travel & lodging$2,32522%
  • Food & beverage$4,17540%
  • Education$1,12811%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,417 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$731,551
Medicare patients
311
Services billed
18,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4631$425,599
BotoxOnabotulinumtoxina57$77,572
Aimovig AutoinjectorErenumab-Aooe18$13,565
UbrelvyUbrogepant13$12,930
Emgality PenGalcanezumab-Gnlm11$8,456
Gabapentin150$2,684
Pregabalin83$2,278
Pyridostigmine Bromide15$2,262
Sumatriptan Succinate20$1,815
Duloxetine Hcl47$1,015
Carbidopa-LevodopaCarbidopa/Levodopa23$815
Baclofen22$619
Tizanidine Hcl51$477
RizatriptanRizatriptan Benzoate14$357
Morphine Sulfate ErMorphine Sulfate12$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$35$425,59931 claims
AbbVieBotox, Ubrelvy$449$90,50270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →